HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Aspartic Acid (Aspartate)

Subscribe to New Research on Aspartic Acid

One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.

Also Known As:

Aspartate; L-Aspartic Acid; L-Aspartate; Magnesium Aspartate; (+-)-Aspartic Acid; (R,S)-Aspartic Acid; Ammonium Aspartate; Aspartate Magnesium Hydrochloride; Aspartic Acid, Ammonium Salt; Aspartic Acid, Calcium Salt; Aspartic Acid, Dipotassium Salt; Aspartic Acid, Disodium Salt; Aspartic Acid, Hydrobromide; Aspartic Acid, Hydrochloride; Aspartic Acid, Magnesium (1:1) Salt, Hydrochloride, Trihydrate; Aspartic Acid, Magnesium (2:1) Salt; Aspartic Acid, Magnesium-Potassium (2:1:2) Salt; Aspartic Acid, Monopotassium Salt; Aspartic Acid, Monosodium Salt; Aspartic Acid, Potassium Salt; Aspartic Acid, Sodium Salt; Calcium Aspartate; Dipotassium Aspartate; Disodium Aspartate; Magnesiocard; Mg-5-Longoral; Monopotassium Aspartate; Monosodium Aspartate; Potassium Aspartate; Sodium Aspartate; Aspartate, Ammonium; Aspartate, Calcium; Aspartate, Dipotassium; Aspartate, Disodium; Aspartate, Magnesium; Aspartate, Monopotassium; Aspartate, Monosodium; Aspartate, Potassium; Aspartate, Sodium; Hydrobromide Aspartic Acid; Hydrochloride Aspartic Acid; Hydrochloride, Aspartate Magnesium; L Aspartate; L Aspartic Acid; Mg 5 Longoral; Mg5Longoral

Networked: 2382 relevant articles (63 outcomes, 206 trials/studies)

Relationship Network

Drug Context: Research Results

Amino Acids, Peptides, and Proteins
- Amino Acids: 10808

Experts

1.	Chen, Xiaoyuan: 7 articles (08/2014 - 03/2005)
2.	Kharitonova, M V: 7 articles (04/2013 - 08/2007)
3.	Kravchenko, M S: 7 articles (04/2013 - 08/2007)
4.	Iezhitsa, I N: 7 articles (04/2013 - 08/2007)
5.	Nissim, I: 7 articles (12/2001 - 03/2000)
6.	Spasov, A A: 6 articles (04/2013 - 08/2007)
7.	Phillis, J W: 6 articles (09/2003 - 01/2000)
8.	O'Regan, M H: 6 articles (09/2003 - 01/2000)
9.	Liu, Bin: 5 articles (02/2015 - 03/2011)
10.	Studneva, I M: 5 articles (11/2008 - 01/2004)

Related Diseases

1.	Body Weight (Weight, Body) 12/01/2011 - "A carrier control group was administered diet with no added NAA and a comparative control group was given aspartate (ASP), the constituent amino acid of NAA, at a target dose of 500 mg/kg of body weight/day. " 11/01/1997 - "Newborn male and female rat pups were injected with either 2 mg or 4 mg monosodium aspartate (MSA)/g body weight or diluent on alternate days for the first 9 days of life. " 01/01/1988 - "When carbohydrate (1 g/kg body weight) was administered simultaneously no lesions were detected in mice administered 750 mg/kg body weight aspartate, while 30.1 +/- 14.2 necrotic neurons/section were noted at 1000 mg aspartate/kg body weight. " 11/01/1987 - "The addition of 10 mg APM/kg body weight to the beverage had no significant effect on plasma aspartate concentration. " 02/01/1985 - "A modest, but significant effect of carbohydrate was noted on the mean peak plasma aspartate levels in animals administered 1000 mg/kg body weight aspartate (P less than 0.05, Student's t-test). "
2.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 12/01/1992 - "A single aspartate is not protective against insulin-dependent diabetes mellitus in Hispanic subjects." 11/01/1992 - "DNA sequence analysis of class II HLA from Caucasian and black patients with type 1 (insulin-dependent) diabetes mellitus has suggested that aspartic acid at position 57 (Asp 57) of the DQ beta chain provides protection against insulin-dependent diabetes mellitus (IDDM). " 02/01/1990 - "Therefore, the Asp 57 hypothesis that the presence of an aspartic acid at position 57 of DQ beta-chain provides protection against developing IDDM is not tenable for Japanese IDDM patients. " 01/01/2005 - "The aspartic acid at position 57 in the DQB1 molecule as in DQB1*0401 is reported to play a role in the resistance to IDDM. " 10/01/1999 - "We formulate the hypothesis that suceptibility to IDDM is not only explained by the absence of Aspartate 57 (negative charge) from pocket 9 of DQB1 (P9DQ), but also by the presence of an electric charge (+/- vs. neutral), generated by residues 70, 71 and 74 in pockets 4 of DRB1 (P4DR) and DQB1 (P4DQ) molecules. "
3.	Ischemia 10/01/2013 - "Hippocampal cysteinyl aspartate-specific protease-3 (caspase-3) activity, nitrite/nitrate contents (NOX), as well as COX-2 immunoreactivity in the hippocampal Cornu Ammonis 1 (CA1) subregion were dramatically increased 24 hours after global ischemia. " 01/01/2013 - "Aspartate release was prominently enhanced by both ischemia and K(+) stimulation in the adult cerebral cortex. " 08/01/2007 - "Aspartate application accelerated the rates of FC-induced mitochondrial depolarization, and, at 1 mmol/L, induced astrocytic death, suggesting that strong energetic demands during ischemia can compromise astrocytic function and viability." 08/01/2004 - "Tissue final aspartic acid level, however, was doubled by ischemia. " 08/01/2003 - "Aspartate immunoreactivity was significantly elevated at 4 and 6 min post-ischemia in neurons, prior to a change in any other amino acid. "
4.	Neoplasms (Cancer) 01/01/2016 - "Aspartate β-hydroxylase (ASPH) was found to link these upstream growth factor signaling pathways to downstream Notch activation in tumor tissues. " 04/01/2014 - "Our results indicated that aspartate metabolism is a significant and differentiable metabolic pathway of HCC compared with non-tumor liver (p value < 0.0001). " 05/01/2012 - "Aspartate-β-hydroxylase (ASPH) is an attractive cellular target since it is a highly conserved transmembrane protein overexpressed in both murine and human HCC tumors, and promotes a malignant phenotype as characterized by enhanced tumor cell migration and invasion. " 03/01/2008 - "Five new CYLD mutations in skin appendage tumors and evidence that aspartic acid 681 in CYLD is essential for deubiquitinase activity." 01/01/2001 - "Structural variations of the L-aspartic acid substructure of (S)-N-3-phenoxycinnamoylaspartic acid dimethyl ester which shows a selective antiproliferative activity against THP-1 tumor cells, demonstrated that the L-aspartic acid moiety is absolutely mandatory for antiproliferative activity as well as for selectivity."
5.	Seizures (Seizure) 12/01/1998 - "Higher doses (100 nmol/0.5 microl) of 2-a-3-arsonopropionate the analogue of aspartate increased the generalized seizure threshold by 40% (P < or = 0.025), while 2-a-4-arsonobutyrate was not effective even at high doses." 10/01/1998 - "Seizures induced with Thiosemicarbaside, Pentylenetetrasole, N-methyl-D,L-aspartate were used as models. " 03/01/1996 - "On the other hand, N-methyl-DL-aspartate (NMDLA; 300 mg/kg or 350 mg/kg, IP) induced clonic seizure, but tonic seizure was not always noted. " 08/01/1994 - "Thus, enhanced aspartate release precedes the onset of EL seizures and may be related to the cause rather than to the effects of seizure activity." 04/21/1994 - "The facilitating or antagonizing effects of polyamine analogues on N-methyl-DL-aspartate (NMDLA)-induced seizures were investigated using mice. "

Related Drugs and Biologics

1.	Glutamic Acid (Glutamate)
2.	Alanine (L-Alanine)
3.	Tyrosine (L-Tyrosine)
4.	Glycine (Aminoacetic Acid)
5.	Arginine (L-Arginine)
6.	Transferases
7.	Methionine (L-Methionine)
8.	Lysine (L-Lysine)
9.	L-Lactate Dehydrogenase (Lactate Dehydrogenase)
10.	Peptides

Related Therapies and Procedures

1.	Transplantation (Transplant Recipients)
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Heterologous Transplantation (Xenotransplantation)
4.	Oral Administration
5.	Transplants (Transplant)